Unknown

Dataset Information

0

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.


ABSTRACT:

Background

Various cardioprotective approaches have been evaluated to prevent chemotherapy-related cardiotoxicity; however, their overall utility remains uncertain.

Objectives

To assess the effects of neurohormonal therapies in preventing cardiotoxicity in patients receiving chemotherapy.

Methods

This meta-analysis included randomized clinical trials of adult patients that underwent chemotherapy and neurohormonal therapies (beta-blockers, mineralocorticoid receptor antagonists, or ACE inhibitors/ARBs) vs. placebo with follow-up ≥4 weeks. The primary outcome was change in left ventricular ejection fraction (LVEF) from baseline to the end of trial. Other outcomes of interest were measures of LV size, strain, and diastolic function. Pooled estimates for each outcome were reported as standardized mean difference (SMD) and weighted mean difference (WMD) between the neurohormonal therapy and placebo groups using random effects models.

Results

We included 17 trials, collectively enrolling 1,984 participants. In pooled analysis, neurohormonal therapy (vs. placebo) was associated with significantly higher LVEF on follow-up [SMD(95% CI): +1.04(0.57 to 1.50)] but with significant heterogeneity in the pooled estimate (I2 = 96%). Compared with placebo-treated patients, those randomized to neurohormonal therapies experienced a 3.96% (95%CI: 2.9% to 5.0%) less decline in LVEF estimated by WMD, but with significant heterogeneity (I2 = 98%). There was a trend towards lower adverse clinical events with neurohormonal therapy (vs. placebo) without statistical significance [risk ratio(95%CI): 0.80(0.53-1.20) I2 = 71%].

Conclusions

Neurohormonal therapies are associated with higher LVEF in follow-up among cancer patients receiving chemotherapy, although absolute changes in LVEF are small and may be within inter-test variability. Furthermore, significant heterogeneity is observed in the treatment effects across studies highlighting the need for larger trials of cardioprotective strategies.

SUBMITTER: Vaduganathan M 

PROVIDER: S-EPMC7571368 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8352186 | biostudies-literature
| S-EPMC6298890 | biostudies-literature
| S-EPMC6149535 | biostudies-literature
| S-EPMC9569539 | biostudies-literature
| S-EPMC10625941 | biostudies-literature
| S-EPMC4090736 | biostudies-literature
| S-EPMC8782611 | biostudies-literature
| S-EPMC5599271 | biostudies-literature
2019-01-02 | PXD010292 | Pride
| S-EPMC8416464 | biostudies-literature